Low serum levels of brain-derived neurotrophic factor and epidermal growth factor in patients with chronic schizophrenia

Ikeda, Yumiko; Yahata, Noriaki; Ito, Itsuo; Nagano, Masatoshi; Toyota, Tomoko; Yoshikawa, Takeo; Okubo, Yoshiro; Suzuki, Hidenori

doi:10.1016/j.schres.2008.01.017

Cited by 132 publications

(103 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Most of the studies (12/16) measuring serum BDNF documented lower concentrations of this neurothropin in patients with schizophrenia (Carlino et al, 2011;Chen et al, 2009;Grillo et al, 2007;Ikeda et al, 2008;Jindal et al, 2010;Jockers-Schrübl et al, 2004;Pirildar et al, 2004;Rizos et al, 2008;Tan et al, 2005a;Toyooka et al, 2002;Xiu et al, 2009;Zhang et al, 2008); however, in other studies, BDNF concentrations were either increased (Gama et al, 2007;Reis et al, 2008); or normal (Huang et al, 2006;Shimizu et al, 2003) (Table 1). Five out of the 16 researches investigated gender effects, demonstrating either significantly lower or higher serum BDNF levels in males suffering from schizophrenia (Gama et al, 2007).…”

Section: Resultsmentioning

confidence: 97%

“…Most of them (322) did not meet the inclusion criteria, most analyzing val66met BDNF polymorphism, mRNA expression or post-mortem studies. Thus, 17 were finally considered but 16 were actually included in the systematic review (Carlino et al, 2011;Chen et al, 2009;Gama et al, 2007;Grillo et al, 2007;Huang et al, 2006;Ikeda et al, 2008;Jindal et al, 2010;Jockers-Schrübl et al, 2004;Pirildar et al, 2004;Reis et al, 2008;Rizos et al, 2008;Shimizu et al, 2003;Tan et al, 2005a;Toyooka et al, 2002;Zhang et al, 2008). Indeed, as per Authors suggestion, we excluded the study by Zhang et al (2007) (124 patients and 50 controls) since the patients' sample consistently overlapped with that of the study published by Zhang and co-workers in the 2008 (196 patients and 50 controls).…”

Section: Systematic Reviewmentioning

confidence: 99%

“…In relation to the source of recruitment, 6/16 studies included only inpatients Reis et al, 2008;Rizos et al, 2008;Tan et al, 2005a;Xiu et al, 2009;Zhang et al, 2008), 1/16 included only outpatients (Gama et al, 2007), 3/16 considered both in-patients and out-patients (Carlino et al, 2011;Huang et al, 2006;Ikeda et al, 2008) and 6/16 publications did not provide data (Grillo et al, 2007;Jindal et al, 2010;Jockers-Schrübl et al, 2004;Pirildar et al, 2004;Shimizu et al, 2003;Toyooka et al, 2002). In our research, we found that Japanese subjects were investigated in three studies (Ikeda et al, 2008;Shimizu et al, 2003;Toyooka et al, 2002), Caucasians in another four studies (Carlino et al, 2011;JockersSchrübl et al, 2004;Pirildar et al, 2004, Rizos et al, 2008 and Asians in five studies Huang et al, 2006;Tan et al, 2005a, Zhang et al, 2008. In four studies, ethnicity was unspecified (Gama et al, 2007;Grillo et al, 2007, Reis et al, 2008Jindal et al, 2010).…”

Section: Clinical Features Of Patientsmentioning

confidence: 99%

“…In four studies, ethnicity was unspecified (Gama et al, 2007;Grillo et al, 2007, Reis et al, 2008Jindal et al, 2010). Six studies reported no diagnostic subtypes of schizophrenia (Ikeda et al, 2008;Gama et al, 2007;Jockers-Schrübl et al, 2004;Pirildar et al, 2004;Reis et al, 2008;Rizos et al, 2008;Toyooka et al, 2002) while in seven studies it was assessed the differences in serum BDNF levels among diagnostic subtypes Grillo et al, 2007;Huang et al, 2006;Shimizu et al, 2003;Tan et al, 2005a;Xiu et al, 2009;Zhang et al, 2008). Different forms of schizophrenia had no association with BDNF serum levels in 5 papers (Grillo et al, 2007, Shimizu et al, 2003Tan et al, 2005a;Xiu et al, 2009;Zhang et al, 2008), while Chen et al (2009) showed significantly higher BDNF levels in paranoid (10.4 ± 4.3 ng/ml) compared to undifferentiated (8.0 ± 3.9 ng/ml) and other combined subtypes (7.5± 4.1 ng/ml).…”

Section: Clinical Features Of Patientsmentioning

confidence: 99%

“…To assess if BDNF can represent a good biomarker in schizophrenia, a growing number of studies compared BDNF serum levels between patients with schizophrenia and healthy control subjects but unfortunately, with controversial results. Indeed, several investigators found a significant decrease in serum BDNF concentrations (Carlino et al, 2011;Chen et al, 2009;Grillo et al, 2007;Ikeda et al, 2008, Jindal et al, 2010Pirildar et al, 2004;Rizos et al, 2008;Shimizu et al, 2002;Tan et al, 2005aTan et al, , 2005bToyooka et al, 2002;Xiu et al, 2009;Zhang et al, 2007Zhang et al, , 2008; while other studies documented normal (Shimizu et al, 2003;JockersSchrubl et al 2004;Huang et al 2006) or even increased circulating BDNF (Gama et al, 2007;Reis et al, 2008). Because of these discrepancies, we decided to perform a systematic review and a meta-analysis of studies measuring serum concentrations of BDNF to elucidate whether or not this neurotrophin is abnormally produced in patients with schizophrenia.…”

Section: Introductionmentioning

confidence: 98%

See 4 more Smart Citations

State of Art of Serum Brain-Derived Neurotrophic Factor in Schizophrenia

Carlino¹,

Baiano²,

Vanna³

et al. 2011

Psychiatric Disorders - Trends and Developments

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 97%

Section: Systematic Reviewmentioning

confidence: 99%

Section: Clinical Features Of Patientsmentioning

confidence: 99%

Section: Clinical Features Of Patientsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 98%

See 3 more Smart Citations

State of Art of Serum Brain-Derived Neurotrophic Factor in Schizophrenia

Carlino¹,

Baiano²,

Vanna³

et al. 2011

Psychiatric Disorders - Trends and Developments

View full text Add to dashboard Cite

Extracellular Matrix-Glial Abnormalities in the Amygdala and Entorhinal Cortex of Subjects Diagnosed With Schizophrenia

Pantazopoulos

Woo²,

Lim³

et al. 2010

Arch Gen Psychiatry

260

282

View full text Add to dashboard Cite

Context Chondroitin sulfate proteoglycans (CSPGs), a main component of the brain extracellular matrix, regulate developmental and adult neural functions that are highly relevant to the pathogenesis of schizophrenia. Such functions, together with marked expression of CSPGs in astrocytes within the normal human amygdala and evidence of a disruption of astrocytic functions in this disease, point to involvement of CSPG-glial interactions in schizophrenia. Hypothesis Chondroitin sulfate proteoglycan–related abnormalities involve glial cells and extracellular matrix pericellular aggregates (perineuronal nets) in the amygdala and entorhinal cortex of subjects with schizophrenia. Design Postmortem case-control study. Setting The Translational Neuroscience Laboratory at McLean Hospital, Harvard Medical School. Specimens were obtained from the Harvard Brain Tissue Resource Center at McLean Hospital. Participants Two separate cohorts of healthy control (n = 15; n = 10) and schizophrenic (n = 11; n = 10) subjects and a cohort of subjects with bipolar disorder (n=11). Interventions Quantitative, immunocytological, and histological postmortem investigations. Main Outcome Measures Numerical densities of CSPG-positive glial cells and perineuronal nets, glial fibrillary acidic protein-positive astrocytes, and total numbers of parvalbumin-positive neurons in the deep amygdala nuclei and entorhinal cortex. Results In schizophrenia, massive increases in CSPG-positive glial cells were detected in the deep amygdala nuclei (419%–1162%) and entorhinal cortex (layer II; 480%–1560%). Perineuronal nets were reduced in the lateral nucleus of the amygdala and lateral entorhinal cortex (layer II). Numerical densities of glial fibrillary acidic protein-positive glial cells and total numbers of parval-bumin-positive neurons were unaltered. Changes in CSPG-positive elements were negligible in subjects with bipolar disorder. Conclusions Marked changes in functionally relevant molecules in schizophrenia point to a pivotal role for extracellular matrix–glial interactions in the pathogenesis of this disease. Disruption of these interactions, unsuspected thus far, may represent a unifying factor contributing to disturbances of neuronal migration, synaptic connectivity, and GABAergic, glutamatergic, and dopaminergic neurotransmission in schizophrenia. The lack of CSPG abnormalities in bipolar disorder points to a distinctive aspect of the pathophysiology of schizophrenia in key medial temporal lobe regions.

show abstract

Levels of brain‐derived neurotrophic factor in patients with multiple sclerosis

Naegelin

Saeuberli

Schaedelin

et al. 2020

Ann Clin Transl Neurol

View full text Add to dashboard Cite

Objective: To determine the levels of brain-derived neurotrophic factor (BDNF) in the serum of patients suffering from multiple sclerosis (MS) to evaluate the potential of serum BDNF as a biomarker for MS. Methods: Using a recently validated enzyme-linked immunoassay (ELISA) we measured BDNF in patients with MS (pwMS), diagnosed according to the 2001 McDonald criteria and aged between 18 and 70 years, participating in a long-term cohort study with annual clinical visits, including blood sampling, neuropsychological testing, and brain magnetic resonance imaging (MRI). The results were compared with an age-and sex-matched cohort of healthy controls (HC). Correlations between BDNF levels and a range of clinical and magnetic resonance imaging variables were assessed using an adjusted linear model. Results: In total, 259 pwMS and 259 HC were included, with a mean age of 44.42 AE 11.06 and 44.31 AE 11.26 years respectively. Eleven had a clinically isolated syndrome (CIS), 178 relapsing remitting MS (RRMS), 56 secondary progressive MS (SPMS), and 14 primary progressive MS (PPMS). Compared with controls, mean BDNF levels were lower by 8 % (p˂0.001) in pwMS. The level of BDNF in patients with SPMS was lower than in RRMS (p = 0.004). Interpretation: We conclude that while the use of comparatively large cohorts enables the detection of a significant difference in BDNF levels between pwMS and HC, the difference is small and unlikely to usefully inform decision-making processes at an individual patient level.

show abstract

Low serum levels of brain-derived neurotrophic factor and epidermal growth factor in patients with chronic schizophrenia

Cited by 132 publications

References 51 publications

State of Art of Serum Brain-Derived Neurotrophic Factor in Schizophrenia

State of Art of Serum Brain-Derived Neurotrophic Factor in Schizophrenia

Extracellular Matrix-Glial Abnormalities in the Amygdala and Entorhinal Cortex of Subjects Diagnosed With Schizophrenia

Levels of brain‐derived neurotrophic factor in patients with multiple sclerosis

Contact Info

Product

Resources

About